There are 1,342 papers on age-related macular degeneration in aging research: 25 trials and 677 observational studies in people, 116 in animals, 28 in cells, 410 reviews. The newest story, Nov 12, 2026: “Blood protein patterns linked to later macular degeneration”.
Age-related macular degeneration is associated with frailty and accelerated ocular aging in human studies. Human cohorts link malnutrition, metabolic vulnerability and clonal hematopoiesis of indeterminate potential with higher disease risk. A human trial reports no clear effect of omega-3 fatty acids or aspirin on age-related macular degeneration.
1,071 findings in 635 papers from 1996 to 2026, 114 of them since April 2026
“indicated a 23% decreased risk in the cocoa extract group during the first 2 years of treatment (HR, 0.77; 95% CI, 0.59-1.01)”
Mediterranean diet protects against age-related macular degeneration in humans.
“nutrients, such as polyphenols, like resveratrol, carotenoids, especially lutein and zeaxanthin, omega-3 polyunsaturated fatty acids, or the Mediterranean and Oriental dietary patterns, may have a protective effect against AMD”
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·
Mediterranean diet showed no clear effect on age-related macular degeneration in humans (cross-sectional studies) (OR = 0.96 (95% CI: 0.83-1.11)).
“meta-analysis of cross-sectional studies (pooled OR = 0.96; 95% CI: 0.83-1.11; p = 0.6243; I2 = 0%) found no significant association between MD adherence and AMD.”
Aspirin showed no clear effect on age-related macular degeneration in humans (rate ratio 0.88; 95% CI 0.69 to 1.12).
“There was no significant effect of randomisation to aspirin compared with placebo on AMD diagnoses, which were reported by 122 (1.6%) participants assigned aspirin, compared with 138 (1.8%) assigned placebo (rate ratio 0.88; 95% CI 0.69 to 1.12; p=0.31; ).”
Aspirin showed no clear effect on age-related macular degeneration in humans (diabetes but no evident cardiovascular disease) (1.6% vs 1.8%, RR 0.88 (95% CI 0.69-1.12)).
“rate ratio 0.88; 95% CI 0.69 to 1.12; p=0.31”
Human trialdiabetes but no evident cardiovascular disease100 mg daily7.4 yearsn = 15,480
Aspirin showed no clear effect on age-related macular degeneration in humans (RR 1.02, 95% CI 0.85-1.22).
“Cumulative AMD incidence was 195 of 1004 (19.4%) in the aspirin group and 187 of 979 (19.1%) in the placebo group (relative risk [RR], 1.02; 95% CI, 0.85-1.22; P = .86).”
Metformin showed no clear effect on age-related macular degeneration in humans (population at high risk for developing diabetes) (30.2% vs 30.7%).
“There was no significant difference in the presence of AMD between the 3 groups: 152 (29.6%) in the lifestyle arm, 165 (30.2%) in the metformin arm, and 162 (30.7%) in the placebo arm.”
Human trialpopulation at high risk for developing diabetesretinamean [SD], 8.5 [9.3] yearsn = 1,592
Metformin was not clearly linked with age-related macular degeneration in humans (without AMD at baseline, propensity score matched) (RR 0.90, 95% CI 0.86-0.94).
“After propensity score matching, participants prescribed metformin had comparable risk of developing any AMD relative to those not prescribed metformin (RR, 0.90; 95% CI, 0.86-0.94).”
Humanswithout AMD at baseline, propensity score matched
Metformin showed no clear effect on age-related macular degeneration in humans.
“The pooled analysis showed no statistically significant difference between the metformin group and the non-metformin group regarding age-related macular degeneration”
Smoking cessation is linked with lower age-related macular degeneration in humans (10.0% decrease).
“a reduction of smoking exposure to its theoretical minimum risk exposure level (TMREL) would lead to an estimated 10.0% decrease in AMD DALYs in 2021”
Omega-3 fatty acids showed no clear effect on age-related macular degeneration in humans (diabetes but no evident cardiovascular disease) (1.7% vs 1.7%, RR 0.99 (95% CI 0.78-1.27)).
“rate ratio 0.99; 95% CI 0.78 to 1.27; p=0.99”
Human trialdiabetes but no evident cardiovascular disease1 g daily7.4 yearsn = 15,480
Educational level was not clearly linked with age-related macular degeneration in humans (multivariable analysis).
“educational level was not significantly associated with myopic macular degeneration (MMD; P = 0.72), age-related macular degeneration (AMD; P = 0.21)”
Calcifediol was not clearly linked with age-related macular degeneration in humans (weighted CGPS allele score) (HR 1.01, 95% CI 1.00-1.02).
“Genetically, each increase in the 25-hydroxyvitamin D-increasing weighted CGPS allele score was associated with a hazard ratio of 1.01 (95% confidence interval: 1.00-1.02) in CGPS”
Theobroma cacao flavanols showed no clear effect on age-related macular degeneration in humans (composite of incident AMD and progression to advanced AMD, cocoa extract vs placebo) (HR 0.87 (95% CI 0.71-1.08)).
“cocoa extract supplementation for a median period of 3.6 years among older women and men had no effect overall on occurrence of AMD”
Human trialcomposite of incident AMD and progression to advanced AMD, cocoa extract vs placebococoa extract, 500 mg/day cocoa flavanols500 mg/day cocoa flavanolsmedian 3.6 yearsn = 21,442
Lifestyle modification showed no clear effect on age-related macular degeneration in humans (population at high risk for developing diabetes) (29.6% vs 30.7%).
“There was no significant difference in the presence of AMD between the 3 groups: 152 (29.6%) in the lifestyle arm, 165 (30.2%) in the metformin arm, and 162 (30.7%) in the placebo arm.”
Human trialpopulation at high risk for developing diabetesretinan = 1,592
Age-related macular degeneration is linked with worse rod-mediated dark adaptation in humans (early and intermediate AMD) (Minimum Clinically Important Difference at 3 years follow-up).
“Of seven vision tests utilised in ALSTAR2, only RMDA achieved a Minimum Clinically Important Difference at 3 years follow-up.”
Age-related macular degeneration is linked with higher activities of daily living impairment in humans (compared to controls) (92.2% vs 55.6%, p < 0.001).
“More participants with age-related macular degeneration (92.2%) had impairment with one or more activities of daily living as compared to controls (55.6%,p < 0.001).”
Total normalized retinal pigment epithelium reflectivity
↓downin humans1
1 study
Age-related macular degeneration is linked with lower total normalized retinal pigment epithelium reflectivity in humans (intermediate AMD vs eAMD and healthy eyes) (P < 0.01).
“TNRR was lower in iAMD eyes compared to eAMD and healthy eyes (P < 0.01)”
Humansintermediate AMD vs eAMD and healthy eyesretinan = 502
Age-related macular degeneration is linked with lower total retinal pigment epithelium thickness in humans (intermediate AMD vs eAMD and healthy eyes) (P < 0.001).
“TRPET was significantly thinner in iAMD compared with eAMD and healthy eyes (P < 0.001)”
Humansintermediate AMD vs eAMD and healthy eyesretinan = 502
Inflammation is linked with age-related macular degeneration in humans (Exploratory mediation analysis of the eGDR-AMD association) (0.3%–6.6% of the eGDR-AMD association).
“Systemic inflammatory markers (C-reactive protein, neutrophils, neutrophil-lymphocyte ratio, systemic immune-inflammatory index) mediated only a small proportion (0.3%–6.6%) of the eGDR-AMD association.”
HumansExploratory mediation analysis of the eGDR-AMD associationMedian follow-up of 13.4 yearsn = 429,844
Inflammation is linked with age-related macular degeneration in humans (37.5%).
“Specific inflammatory and erythrocyte-related biomarkers partially (37.5%) mediated the incidence of age-related macular degeneration as substantial biological mechanisms following handgrip strength decrease.”
Inflammation is linked with age-related macular degeneration in humans (between low lung function and AMD).
“Inflammatory markers and erythrocyte-related measures mediated this relationship, acting as a pathway through which low lung function influenced AMD.”
Thyroid peroxidase antibody positivity was not clearly linked with age-related macular degeneration in humans (Mutually adjusted observational model) (OR 0.93, 95% CI 0.63–1.37).
“TPOAb positivity was not associated with AMD (OR, 0.93; 95% CI, 0.63-1.37; P = 0.676).”
Severe systemic lupus erythematosus was not clearly linked with age-related macular degeneration in humans (Treatment-defined SLE severity; adjusted analysis).
“Severe SLE was not associated with higher AMD hazards after adjustment.”
HOEM thickness was not clearly linked with age-related macular degeneration in humans (multivariable analysis adjusted for age, axial length, EZ, POS, choroid, RPE/BM) (beta: 0.03; p=0.08).
“thickness of Henle's fibre layer, outer nuclear layer, external limiting membrane and myoid zone (HOEM) combined was not significantly associated with AMD prevalence (beta: 0.03; p=0.08)”
Telomere length was not clearly linked with age-related macular degeneration in humans after adjusting for multiple confounders (HR=1.042, 95% CI: 0.992 to 1.094).
“Shorter LTL was not associated with incident AMD risk (HR=1.042, 95% CI: 0.992 to 1.094; p=0.10) after adjusting for multiple confounders.”
Humansafter adjusting for multiple confoundersn = 332,123
Environmental science and pollution research international·
Smoking is associated with age-related macular degeneration in humans.
“Statistically Significant associations were observed between ARMD and risk factors such as diabetes, hypertension, ischaemic heart disease, high body mass index and smoking.”
Metformin is linked with a lower risk of age-related macular degeneration in humans (type 2 diabetes) (OR 0.63, 95% CI 0.43 to 0.92, p=0.02).
“Metformin was associated with reduced incidence of intermediate AMD by 5 years after adjusting for confounders (complete record OR 0.63, 95% CI 0.43 to 0.92, p=0.02).”
Metformin is linked with a lower risk of age-related macular degeneration in patients with type 2 diabetes mellitus (OR: 0.93, 95% CI: 0.88-0.99).
“patients with T2DM treated with <5 defined daily dose (DDD)/month of metformin had a lower risk of AMD (odds ratios [OR]: 0.93; 95% confidence interval [CI]: 0.88 0.99).”
Humansin patients with type 2 diabetes mellitus<5 DDD/month5 years
Mediterranean diet is linked with a lower risk of age-related macular degeneration in humans after adjusting for confounding factors (adjusted OR 0.58, 95% CI 0.39-0.88).
“Multiple logistic regression analysis revealed a significantly negative association between the aMED score and AMD (adjusted ORs = 0.58; 95% confidence interval = 0.39-0.88; p-trend = 0.021) in older men”
Humansafter adjusting for confounding factorsmalesn = 895
Mediterranean diet is linked with a lower risk of age-related macular degeneration in humans (high adherence vs low adherence to Mediterranean diet) (reduced by 60%).
“The AMD risk was reduced by 60% in subjects with high adherence to the Mediterranean diet compared to subjects with low adherence to the Mediterranean diet.”
Humanshigh adherence vs low adherence to Mediterranean diet
International Journal of Innovative Technologies in Social Science·
Mediterranean diet lowers the risk of age-related macular degeneration in humans (20-56%).
“dietary patterns rich in lutein, zeaxanthin, and omega-3 fatty acids-particularly through green leafy vegetables, fatty fish, and Mediterranean diet adherence-reduce AMD progression risk by 20-56%”
Mediterranean diet lowers the risk of age-related macular degeneration in humans.
“adherence to a Mediterranean diet, rich in vegetables, fruits, legumes, whole grains, and nuts, has been linked to a lower risk of both early and late AMD”
Mediterranean diet lowers the risk of age-related macular degeneration in humans (HR 0.82; 95% CI: 0.75-0.90).
“Subjects with medium-high (hazard ratio [HR] 0.82; 95% confidence interval [CI]: 0.75-0.90) adherence to the MD showed a reduced risk of developing AMD.”
Age is linked with a higher risk of age-related macular degeneration in humans (population-based cohort) (OR per year 1.08, 95% CI 1.05-1.11, p<0.001).
“Multivariate analysis showed that ARMD prevalence increased significantly with age (OR per year 1.08; 95% CI 1.05-1.11, p<0.001)”
Age is linked with a higher risk of age-related macular degeneration in humans (OR: 1.12, 95% CI: 1.04, 1.19, P = 0.001).
“Higher prevalence of any AMD and late AMD was significantly correlated with urban region of habitation (OR:3.34; 95% CI:2.37,4.71; P < 0.001), and with older age (OR:1.12; 95% CI:1.04,1.19; P = 0.001)”
Age is associated with age-related macular degeneration in humans (non-irradiated individuals applying for work involving ionizing radiation).
“the prevalence of age-related macular degeneration in non-irradiated individuals determined in the pilot group was high and statistically significantly increased with age.”
Humansnon-irradiated individuals applying for work involving ionizing radiationretinan = 1,064
Fine particulate matter is associated with age-related macular degeneration in humans (National age-standardized prevalence rates worldwide in 2019) (Prevalence r = 0.67; DALY rate r = 0.54).
“National prevalence rates of VI and three major ocular diseases correlate significantly with PM2.5 exposure levels, worldwide.”
HumansNational age-standardized prevalence rates worldwide in 2019
Fine particulate matter is linked with a higher risk of age-related macular degeneration in humans (highest vs lowest quartile) (OR 2.602 (95% CI 1.516, 4.468)).
“A significant positive association was detected between AMD and PM2.5 level”
Fine particulate matter is associated with age-related macular degeneration in humans.
“fine particulate matter (PM2.5) and nitrogen dioxide (NO2) have the most consistent epidemiological evidence for adverse effects on retinal health, particularly in relation to age-related macular degeneration (AMD).”
Ozone is associated with age-related macular degeneration in humans (Korean adults; fully adjusted analysis) (3-year OR 1.12, 95% CI 1.04–1.22 per IQR increase).
“O3 exposure was significantly associated with higher odds of AMD across all exposure windows”
HumansKorean adults; fully adjusted analysisper interquartile range increase in O3 concentration3-year moving averagen = 13,985
Ozone is linked with a higher risk of age-related macular degeneration in humans (OR 5.42, p < 0.001).
“Multivariable regression analyses identified PM2.5 (odds ratio [OR] 8.09, p < 0.001) and ozone (OR 5.42, p < 0.001) as independent predictors of AMD prevalence.”
Ozone is linked with a higher risk of age-related macular degeneration in humans (warm-season ozone concentration below 110 μg/m3).
“Every 10 μg/m3 increment in warm-season ozone concentration, the adjusted odds ratio (OR) for AMD were 1.15 (1.13, 1.16) and 1.66 (1.63, 1.69) when the warm-season ozone concentration was below or above 110 μg/m3, respectively.”
Statins are linked with a lower risk of age-related macular degeneration in humans (patients with type 2 diabetes and dyslipidemia) (HR 0.74 (95% CI: 0.57-094)).
“High-intensity statin use was associated with a reduced risk of combined AMD at 3 and 5 years (HR: 0.74 (95% CI: 0.57-094) and 0.79 (95% CI: 0.62-0.98), respectively).”
Humanspatients with type 2 diabetes and dyslipidemia3 years
Statins are linked with a lower risk of age-related macular degeneration in humans (adjusted for age, sex, body mass index, smoking, diabetes, and GRS) (48% risk reduction).
“Statin intake reduced the risk for progression to AMD in 48%”
Humansadjusted for age, sex, body mass index, smoking, diabetes, and GRS
Statins lower the risk of age-related macular degeneration in humans (treatment duration exceeding 2 years and medium-intensity to high-intensity dosing).
“treatment duration exceeding 2 years and medium-intensity to high-intensity dosing may confer protection against AMD development”
Reviewtreatment duration exceeding 2 years and medium-intensity to high-intensity dosingmedium-intensity to high-intensityexceeding 2 years
Statins lower the risk of age-related macular degeneration in humans.
“associations between several candidates and decreased risk of AMD development or progression. Such candidates include the more extensively studied metformin and statins”
Hypertension is associated with age-related macular degeneration in humans.
“Statistically Significant associations were observed between ARMD and risk factors such as diabetes, hypertension, ischaemic heart disease, high body mass index and smoking.”
Hypertension raises the risk of age-related macular degeneration in humans (meta-analysis of observational studies) (OR 1.24 (95% CI = 1.09-1.4, P = .0007)).
“hypertension, cardiovascular diseases, and diabetes were statistically significant predictors for AMD occurrence, with ORs of 1.11 (95% CI = 1.06-1.15, P < .00001), 1.63 (95% CI = 1.13-2.35, P = .009), 1.86 (95% CI = 1.33-2.6, P = .0003), 1.24 (95% CI = 1.09-1.4, P = .0007)”
Theobroma cacao flavanols lower the risk of age-related macular degeneration in humans (first 2 years of treatment, separate Cox models for nonproportional hazards) (23% decreased risk; HR 0.77 (95% CI 0.59-1.01)).
“indicated a 23% decreased risk in the cocoa extract group during the first 2 years of treatment (HR, 0.77; 95% CI, 0.59-1.01)”
Human trialfirst 2 years of treatment, separate Cox models for nonproportional hazardscocoa extract, 500 mg/day cocoa flavanols500 mg/dayfirst 2 years
Human cohorts link frailty, frailty progression and accelerated ocular aging with higher age-related macular degeneration risk. Healthy plant-based and Mediterranean diets are associated with lower risk, whereas a human trial shows no clear effect of omega-3 fatty acids or aspirin on the disease.
Summary rewritten as its findings changed.
As it read before
Age-related macular degeneration is associated with frailty and accelerated biological and ocular aging in human studies, and with higher mortality in a cohort at high cardiovascular risk. Observational studies link metformin use in people with type 2 diabetes to lower risk, while a human trial shows no clear effect of omega-3 fatty acids or aspirin.
Summary rewritten as its findings changed.
As it read before
Human studies associate age-related macular degeneration with frailty, accelerated biological and ocular aging, and impaired vision and daily activities. Cohorts link malnutrition and cardiometabolic disease to higher AMD risk, while studies in people with type 2 diabetes associate metformin use with lower risk; a cohort of people at high cardiovascular risk links AMD to higher mortality.
Frailty, malnutrition and higher metabolic vulnerability are associated with higher age-related macular degeneration risk in human cohorts. Human studies also link the disease to accelerated ocular aging. A human trial reports lower risk with antioxidant and zinc tablets over 6.3 years.
Summary rewritten as its findings changed.
As it read before
In human cohorts, higher oxidative balance scores lower the risk of age-related macular degeneration, whereas CETP inhibitors, vitamin D insufficiency and vitamin D deficiency increase disease risk.
Experiments in retinal pigment epithelium cells linked reduced receptor activity to defects resembling those seen in age-related macular degeneration.Experiments in retinal pigment epithelium cells linked reduced receptor activity to defects resembling those seen in age-related macular degeneration.
What changedRetinal pigment cells lacking the receptor or exposed to receptor-blocking drugs developed weaker barriers and problems processing cellular waste
The catchExperiments measured cellular defects, not vision preservation or prevention of age-related macular degeneration
Blood protein patterns in 45,379 people varied with time to diagnosis, with one protein group’s average pattern changing approximately nine years before diagnosis.Blood protein patterns in 45,379 people varied with time to diagnosis, with one protein group’s average pattern changing approximately nine years before diagnosis.
A genetic analysis in European populations linked 22 groups of gut microbes and 59 blood metabolites to age-related macular degeneration risk.A genetic analysis in European populations linked 22 groups of gut microbes and 59 blood metabolites to age-related macular degeneration risk.